Our team develops a wide range of genetically engineered mouse and cell line models, from knockouts and point mutations to protein tagging, conditional and inducible expression, and humanised systems. Alongside building novel models, we run end-to-end preclinical studies in neurological, autoimmune, and tumour disease models. These capabilities allow us to investigate gene function, validate therapeutic targets, and test both small molecule and genetic therapies. We also enhance existing transgenic lines with new alterations and design controllable systems for gene up- and down-regulation. Explore some of our projects below.